Erschienen in:
18.09.2017 | Review articles
Quantitative evaluation of PPAR-γ2 Pro12Ala polymorphism with hypertension
verfasst von:
W. Yang, J. Wang, W. Ye, Dr. X. Li
Erschienen in:
Herz
|
Ausgabe 8/2018
Einloggen, um Zugang zu erhalten
Abstract
Background
The peroxisome proliferator-activated receptor γ2 (PPARγ2)Pro12Ala polymorphism has been reported to be associated with hypertension. However, relevant studies have shown inconsistent results.
Methods
To quantitatively evaluate the relationship between the PPARγ2Pro12Ala polymorphism and hypertension risk, we conducted a meta-analysis based on all available studies selected from Scopus, Web of Science, PubMed, Chinese National Knowledge Infrastructure, and Wanfang databases.
Results
In all, 13 studies were finally included in this meta-analysis. In the allelic model (Ala vs. Pro), the Ala allele of PPARγ2 Pro12Ala polymorphism was associated with hypertension (Odds Ratio [OR] = 0.723, 95% confidence interval [CI] = 0.607–0.861). Sensitivity analysis and exclusion of studies with poor quality scores or controls complicated by other diseases confirmed the validity of this association. Moreover, the PPARγ2Pro12Ala polymorphism was associated with hypertension in the codominant (OR = 0.710, 95% CI = 0.626–0.806), recessive (OR = 0.561, 95% CI = 0.418–0.754), and dominant (OR = 0.693, 95% CI = 0.577–0.833) models.
Conclusion
The Ala allele appears to have a protective effect against hypertension and a dominant function.